Evommune (EVMN) Other Non-Current Assets (2024 - 2026)
Evommune (EVMN) posted quarterly Other Non-Current Assets of $73000.0 for Q1 2026, down 64.9% year-over-year from $208000.0 in Q1 2025, and down 27.72% quarter-over-quarter from $101000.0 in Q4 2025.
Evommune (EVMN) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Other Non-Current Assets for 3 consecutive years, with $73000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 64.9% year-over-year to $73000.0; the TTM figure through Mar 2026 stood at $73000.0 (down 64.9% YoY), while the FY2025 annual figure was $101000.0, down 51.44% from the prior year.
- Other Non-Current Assets declined to $73000.0 in Q1 2026 per EVMN's latest filing, from $101000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.4 million in Q3 2025 and bottomed at $73000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $368333.3 across 3 years, with a median of $208000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets surged 578.85% — and 2026, when it slumped 64.9%.
- Evommune's Other Non-Current Assets stood at $208000.0 in 2024, then slumped by 51.44% to $101000.0 in 2025, then retreated by 27.72% to $73000.0 in 2026.
- Business Quant data shows EVMN's Other Non-Current Assets at $73000.0 in Q1 2026, $101000.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Sep 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 208,000.00 |
| Dec 31, 2024 | 208,000.00 |
| Sep 30, 2024 | 208,000.00 |